[1]Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474(7350):212-215.
[2]Lister R, Pelizzola M, Kida YS, et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature. 2011;471(7336):68-73.
[3]赵然,周光纪. 诱导性多能干细胞的表观遗传学调控差异及其与诱导移植排斥的关系[J].细胞与分子免疫学杂志,2013,29(10): 1102-1105.
[4]Tan Y, Ooi S, Wang L. Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives. Curr Stem Cell Res Ther. 2014;9(1): 63-72.
[5]Guha P, Morgan JW, Mostoslavsky G, et al. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell. 2013;12(4): 407-412.
[6]Araki R, Uda M, Hoki Y, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells.Nature. 2013;494(7435):100-104.
[7]Morizane A, Doi D, Kikuchi T, et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports. 2013;1(4):283-292.
[8]Luo W, Li S, Peng B, et al. Embryonic stem cells markers SOX2, OCT4 and Nanog expression and their correlations with epithelial-mesenchymal transition in nasopharyngeal carcinoma. PLoS One. 2013;8(2):e56324.
[9]Lowry WE, Richter L, Yachechko R, et al. Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A. 2008;105(8):2883-2888.
[10]Herreros-Villanueva M, Bujanda L, Billadeau DD, et al. Embryonic stem cell factors and pancreatic cancer. World J Gastroenterol. 2014;20(9):2247-2254.
[11]Nori S, Okada Y, Nishimura S, et al. Long-Term Safety Issues of iPSC-Based Cell Therapy in a Spinal Cord Injury Model: Oncogenic Transformation with Epithelial-Mesenchymal Transition. Stem Cell Reports. 2015;4(3):360-373.
[12]Chen L, Mizutani A, Kasai T, et al. Mouse induced pluripotent stem cell microenvironment generates epithelial- mesenchymal transition in mouse Lewis lung cancer cells. Am J Cancer Res. 2014;4(1):80-88.
[13]Yamaguchi S, Marumoto T, Nii T, et al. Characterization of common marmoset dysgerminoma-like tumor induced by the lentiviral expression of reprogramming factors. Cancer Sci. 2014;105(4):402-408.
[14]Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell. 2008;3(6):595-605.
[15]Eggenschwiler R, Cantz T. Induced pluripotent stem cells generated without viral integration. Hepatology. 2009; 49(3):1048-1049.
[16]Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 2008;322(5903):949-953.
[17]Tóth A, Fodor K, Blazsó P, et al. Generation of induced pluripotent stem cells by using a mammalian artificial chromosome expression system. Acta Biol Hung. 2014;65(3): 331-345.
[18]Chen Q, Shi X, Rudolph C, et al. Recurrent trisomy and Robertsonian translocation of chromosome 14 in murine iPS cell lines. Chromosome Res. 2011;19(7):857-868.
[19]Gore A, Li Z, Fung HL, et al. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011; 471(7336):63-67.
[20]Hussein SM, Batada NN, Vuoristo S, et al. Copy number variation and selection during reprogramming to pluripotency. Nature. 2011;471(7336):58-62.
[21]Lu X, Zhao T. Clinical therapy using iPSCs: hopes and challenges. Genomics Proteomics Bioinformatics. 2013; 11(5):294-298.
[22]Fu X. The immunogenicity of cells derived from induced pluripotent stem cells. Cell Mol Immunol. 2014;11(1):14-16.
[23]Okano H, Nakamura M, Yoshida K, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res. 2013;112(3):523-533.
[24]陈倩,史庆华. iPS 细胞的遗传安全性[J].遗传,2012,34(3): 260-268.
[25]Harding J, Mirochnitchenko O. Preclinical studies for induced pluripotent stem cell-based therapeutics. J Biol Chem. 2014; 289(8):4585-4593.
[26]Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474(7350):212-215.
[27]Cao J, Li X, Lu X, et al. Cells derived from iPSC can be immunogenic - yes or no. Protein Cell. 2014;5(1):1-3.
[28]Miyoshi N, Ishii H, Nagano H, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell. 2011;8(6):633-638. |